Tagged: econsent
8 results
Castor
Castor is a health-technology company that builds a cloud-based eClinical platform for running clinical trials - from electronic data capture (EDC) and eConsent to eCOA/ePRO and real-world evidence. Founded in 2012 in Amsterdam by physician-researcher Dr. Derk Arts, Castor set out to replace clunky, expensive trial software with a self-service, researcher-friendly system. Today it supports more than 15,000 studies across 90+ countries and is used by leading CROs and biopharma companies, while pushing decentralized trials and practical AI (Castor Catalyst, built with Google Cloud) into mainstream research.
Derk Arts
Derk Arts is a Dutch physician-turned-entrepreneur and the founder and CEO of Castor, a clinical-trial software company he started in 2012 after coding the first version of its Electronic Data Capture platform himself. Trained as a medical doctor and epidemiologist with a PhD, he built Castor to make clinical research more inclusive, patient-centric, and data-driven. The platform now supports thousands of trials across roughly 90 countries and was used by the World Health Organization for its Solidarity Trial. Castor has raised more than $60 million, including a $45 million Series B in 2021, and Arts is a recognized voice on decentralized trials, eConsent, and the responsible use of AI in research.
ClinCapture
ClinCapture is an eClinical software company that builds cloud-based tools for running clinical trials - electronic data capture (EDC), ePRO/eCOA, eConsent, randomization, medical coding, and trial master file management. Born from consulting firm Clinovo and once known as the only free, fully validated open-source EDC in the world, it now markets a unified, AI-augmented platform called Captivate that lets sponsors and CROs design, launch, and manage studies from a single validated cloud system.
Curebase
Curebase is a San Francisco-based eClinical software company building an AI-powered platform that runs clinical trials around patients' lives instead of inside hospital walls. Its single system spans study startup to database lock - combining electronic data capture (EDC), eConsent, ePRO/eCOA, patient recruitment, and a virtual research site model - so sponsors can launch decentralized and hybrid trials faster, capture cleaner data, and reach more diverse participant populations.
Medidata Solutions
Medidata Solutions is a New York-based, cloud software company that runs the digital plumbing of modern clinical research. Its flagship Rave EDC pioneered electronic data capture in clinical trials, and today its unified platform spans data capture, patient engagement, AI analytics, imaging, and trial operations. A Dassault Systèmes company since 2019, Medidata powers trials for most of the world's largest pharmaceutical companies and has supported the development of a large share of newly approved drugs and medical devices.
Medable
Medable is a Palo Alto-based digital health company building a cloud SaaS platform for decentralized and hybrid clinical trials. Its tools - eCOA+, Total Consent, Sensors, and Televisit - let pharma sponsors and CROs run studies remotely, enrolling patients in over 60 countries and 120+ languages.
Medrio
Medrio is a San Francisco-based eClinical software company that helps pharma, biotech, medtech and diagnostics teams run clinical trials with a no-code, cloud-based EDC, eCOA/ePRO, eConsent and RTSM suite. Founded in 2005 and bootstrapped for more than a decade before taking outside capital, Medrio now powers thousands of studies across four continents.
Tom Lemberg
Tom Lemberg is the Founder & CEO of Curebase, a San Francisco-based decentralized clinical trial platform that has enrolled over 60,000 patients across 60+ studies. A Harvard-trained computer scientist and molecular biologist, Lemberg built Curebase from his couch in 2017, joined Y Combinator in 2018, and raised $59M to transform how clinical trials work - letting patients participate from home and bringing their own doctors into the research process. Named to Forbes 30 Under 30 in 2022, he's on a mission to make clinical trials accessible to any patient, anywhere.